Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + moxonidine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of valsartan, an angiotensin II receptor blocker (ARB), and moxonidine, an imidazoline/α-2 receptor agonist. Both medications are used to treat hypertension through different mechanisms. Valsartan blocks angiotensin II from binding to AT1 receptors, preventing vasoconstriction and reducing blood pressure. Moxonidine acts on imidazoline I1 receptors and α-2 adrenergic receptors in the central nervous system to reduce sympathetic activity and lower blood pressure.
02
Targets
ADRA2A (α2A)AGTR1 (Angiotensin II Type-1 receptor)I1R (Nischarin)
Beyond the preview
Go deeper on valsartan + moxonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + moxonidine.